Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trialJonas Bergh, Nils Wilking, Tom Wiklund et al.|The Lancet|2000Cited by 343
Model Describing the Relationship Between Pharmacokinetics and Hematologic Toxicity of the Epirubicin-Docetaxel Regimen in Breast Cancer PatientsMarie Sandström, Mats O. Karlsson, Elisabet Lidbrink et al.|Journal of Clinical Oncology|2004Cited by 76
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapyNils Wilking, Jonas Bergh, Elisabet Lidbrink et al.|Annals of Oncology|2007Cited by 36
The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: Data from the randomised SBG 2000-1 studyMikkel Rosendahl, Michael Andersson, Johan Ahlgren et al.|European Journal of Cancer|2009Cited by 21
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancerSara Margolin, Nils‐Olof Bengtsson, Lena Carlsson et al.|Acta Oncologica|2010Cited by 19